Impact of new-onset diabetes mellitus and glycemic control on the prognosis of heart failure patients: a propensity-matched study in the community

International Journal of Cardiology
Sotero P RomeroFrancisco Gomez

Abstract

To assess the incidence of type 2 diabetes mellitus (DM) in patients with heart failure (HF), and to evaluate the effect of new-onset DM and glycemic control on the prognosis of HF patients treated with a contemporary medical regimen. Prospective study of 5314 HF patients and previously unknown DM during 9 years. Their mean age was 71.8 ± 7.9 years, 53.0% were women, and 50.2% had non-systolic HF. During a median follow-up of 56.9 ± 18.2 months, 68.9% of the patients died, 88.6% were hospitalized for HF, and 1519 (27.3%) developed new-onset DM. We propensity-matched those 1519 HF patients with DM, with 1519 HF patients non-diagnosed with DM. The age- and sex-adjusted incidence (per 100 HF patients/years) of DM in HF patients was 3.20, higher in women and in patients with non-systolic HF (p<0.01). Patients with HF and DM and those with a mean HbA1c>7.0% presented an increased mortality (HR of death [CI 95%]: 2.44 [1.68-3.19] and, HR: 2.56 [1.77-3.35], respectively), mainly due to an increased cardiovascular mortality (HR ≥ 2.40 [1.46-3.34]) (P<0.001). The rate of hospitalization, of 30-day readmissions, and the number of visits were higher among HF patients with DM or with HbA1c>7.0% (p<0.001). These relationships of DM and its ...Continue Reading

References

Dec 23, 1971·The New England Journal of Medicine·P A McKeeW B Kannel
Jun 8, 2001·Circulation·C IribarrenJ V Selby
Jan 9, 2003·JAMA : the Journal of the American Medical Association·Margaret M RedfieldRichard J Rodeheffer
Sep 6, 2003·Journal of the American College of Cardiology·Michael DomanskiUNKNOWN BEST Investigators
Nov 20, 2003·JAMA : the Journal of the American Medical Association·Douglas S LeeJack V Tu
Mar 5, 2004·Journal of the American College of Cardiology·Ida GustafssonUNKNOWN Danish Investigatord of Arrhythmia and Mortality on Dofetilde Study Group
Sep 24, 2004·Pharmacoepidemiology and Drug Safety·Donald B Rubin
Jan 12, 2005·Archives of Internal Medicine·Joel G RayJack V Tu
Apr 16, 2005·Heart·Philip M Mottram, Thomas H Marwick
Nov 2, 2006·JAMA : the Journal of the American Medical Association·Alan S GoJerry H Gurwitz
Dec 11, 2007·Journal of Cardiac Failure·Masoor Kamalesh
Nov 18, 2008·European Journal of Internal Medicine·Francisco M Gomez-SotoUNKNOWN Grupo para la Atención Médica Integral y Contínua of Cádiz
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Jan 30, 2009·JAMA : the Journal of the American Medical Association·Ileana L Piña, Christopher O'Connor
Apr 29, 2009·Journal of Cardiac Failure·Masoor Kamalesh, Ton J Cleophas
Jul 25, 2009·Journal of the American College of Cardiology·David AguilarAnita Deswal
May 18, 2010·International Journal of Cardiology·Francisco M Gomez-SotoFrancisco Gomez
Jan 14, 2011·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Apr 17, 2014·Der Internist·A HummelS B Felix
Nov 1, 2013·Heart Failure Reviews·Maya GuglinAnthony Morrison
Feb 27, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Leon VarjabedianNader D Nader
Sep 25, 2018·International Journal of Clinical Practice·Marcos GuzmanFrancisco Gomez
May 22, 2016·BMC Cardiovascular Disorders·Saul BleckerStuart D Katz
Jun 2, 2020·World Journal of Diabetes·Stelina Alkagiet, Konstantinos Tziomalos
Feb 21, 2021·Cardiovascular Diabetology·Sibille LejeuneAnne-Catherine Pouleur

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.